Partnering in Technologies
The need for innovative technologies to accelerate pharmaceutical research and development has never been greater. Seeking to be at the forefront of cutting-edge science, we are expanding our growing global network of technology partners to complement our own expertise in research, development and translational medicine.
Our experience
Scientists at our major research sites, together with our academic and industry partners, are pursuing novel technologies to support therapeutic advances in areas of key unmet medical need. We have the ambition to identify and translate the most promising technology innovations into impactful applications across a broad range of research fields.
Our Technology Partnering Interests
Our partnering interests offer various opportunities for collaboration:
- Applications of artificial intelligence and machine learning in drug discovery and translational sciences
- Development of advanced computational biology methods and analytics to support data-driven new therapeutic concepts
- Platform and enabling technologies enhancing our NCE capabilities or supporting our therapeutic areas
- Lead/tool generation: Technologies for rapid generation of probes/tools for the validation of new therapeutic concepts (e.g., orphan GPCRs)
- Accelerating timelines from tool to lead, lead to drug as well as in drug development
- New modalities beyond small molecules to address difficult targets and expand our NCE target space
- New mode of actions for hard-to-drug therapeutic targets
- Technologies for phenotypic screens, including target deconvolution
- Approaches and technologies that enable small molecules as modalities for RNA targets
- (Targeted) Intracellular delivery technologies
- Long-acting injectables for sustained drug release.
Our Biotherapeutic Technology Partnering Interests
Our specific partnering interests offer various opportunities for collaboration:
- In-silico and AI discovery and optimization platforms for biotherapeutics
- Biologic enabling technologies supporting therapeutic areas (CardioMetabolic diseases, Central Nervous System diseases, Immunology and Inflammation, Oncology, Respiratory diseases and Retinal Health)
- New technologies for intracellular delivery of antibodies
- Technologies to enable function-driven first-in-class antibody identification
- New technologies for half-life extension systemically and in the eye
- Accelerating timelines from tool to lead, lead to drug, as well, as in drug development.